Global Delivery of Human Papillomavirus Vaccines

Pediatric Clinics of North America

Volumn 63, Issue 1, 2016, Pages 81-95

  Wigle, Jannah ^a   Fontenot, Holly B ^b   Zimet, Gregory D ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BOSTON COLLEGE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Global; HPV; Human papillomavirus; Immunization; Progress; Vaccine

Indexed keywords

WART VIRUS VACCINE;

CHILD HEALTH CARE; COMMUNITY PROGRAM; CULTURAL ANTHROPOLOGY; DENMARK; DRUG COST; DRUG LEGISLATION; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HUMAN; PAPILLOMAVIRUS INFECTION; PILOT STUDY; POLITICS; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; REVIEW; SCHOOL HEALTH SERVICE; SOCIOECONOMICS; UNITED STATES; VACCINATION; ADOLESCENT; COMMUNITY CARE; FEMALE; HEALTH; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; COMMUNITY HEALTH SERVICES; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SCHOOL HEALTH SERVICES; UTERINE CERVICAL NEOPLASMS;

EID: 84952815087     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2015.08.004     Document Type: Review

References (91)

1. Forman D., de Martel C., Lacey C.J., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl 5):F12-F23.
2. Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2015-04-08;2015. Available at: . Accessed September 27, 2015. http://www.hpvcentre.net/summaryreport.php.
3. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon (France), Available at:, Accessed May 19, 2015. http://globocan.iarc.fr.
4. Centers for Disease Control and Prevention, United States Cancer Statistics (USCS). Available at: . Accessed July 27, 2015. http://www.cdc.gov/cancer/hpv/statistics/cases.htm.
5. Centers for Disease Control & Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2010, 59:626-627.
6. Centers for Disease Control & Prevention Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007, 56(No. RR-2):1-26.
7. Centers for Disease Control & Prevention FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59:630-632.
8. Petrosky E., Bocchini J.A., Hariri S., et al. Use of 9-Valent Human Papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015, 64:300-304.
9. La Torre G., de Waure C., Chiaradia G., et al. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007, 25:8352-8358.
10. Joura E.A., Giuliano A.R., Iversen O.E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372:711-723.
11. Drolet M., Benard E., Boily M.C., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015, 15:565-580.
12. Scheller N.M., Svanstrom H., Pasternak B., et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015, 313:54-61.
13. Markowitz L.E., Tsu V., Deeks S.L., et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30:F139-F148.
14. Cervical Cancer Action. Global maps: global progress in HPV vaccination. 2015. Available at: . Accessed May 27, 2015. http://www.cervicalcanceraction.org/comments/comments3.php.
15. U.S. Food & Drug Administration. FDA approves Gardasil 9 for prevention of certain cancers caused by 5 additional types of HPV. 2014. Available at: . Accessed May 31, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm.
16. World Health Organization Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations. Vaccine 2015, 33(36):4383-4384.
17. U.S. Department of Health & Human Services. Healthy People 2020. 2015. Available at: . Accessed May 31, 2015. http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives.
18. Elam-Evans L.D., Yankey D., Jeyarajah J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 Years-United States, 2013. MMWR Morb Mortal Wkly Rep 2014, 63:625-633.
19. Shearer B.D. HPV vaccination: understanding the impact on HPV disease. Purple Paper 2011, 34:1-18.
20. Brotherton J.M., Murray S., Hall M., et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 2013, 199:614-617.
21. Franceschi S. Monitoring HPV 16/18 immunisation in England and elsewhere. Br J Cancer 2010, 103:157-158.
22. Widgren K., Simonsen J., Valentiner-Branth P., et al. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011, 29:9663-9667.
23. Binagwaho A., Wagner C.M., Gatera M., et al. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012, 90:623-628.
24. Singh Y., Shah A., Singh M., et al. Human papilloma virus vaccination in Nepal: an initial experience in Nepal. Asian Pac J Cancer Prev 2010, 11:615-617.
25. Watson-Jones D., Baisley K., Ponsiano R., et al. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis 2012, 206:678-686.
26. Sauvageau C., Duval B., Gilca V., et al. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007, 7:304.
27. Lenehan J.G., Leonard K.C., Nandra S., et al. Women's knowledge, attitudes, and intentions concerning human papillomavirus vaccination: findings of a waiting room survey of obstetrics-gynaecology outpatients. J Obstet Gynaecol Can 2008, 30:489-499.
28. Liau A., Stupiansky N.W., Rosenthal S.L., et al. Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women. Prev Med 2012, 54:277-279.
29. GAVI. Human papillomavirus vaccine support. 2015. Available at: . Accessed April 20, 2015. http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support.
30. GAVI. Gavi welcomes lower prices for life-saving vaccines. 2011. Available at: . Accessed May 27, 2015. http://www.gavi.org/library/news/press-releases/2011/gavi-welcomes-lower-prices-for-life-saving-vaccines.
31. GAVI. Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals. 2013. Available at: . Accessed May 27, 2015. http://www.gavi.org/library/news/press-releases/2013/hpv-price-announcement.
32. Levin C.E., Van Minh H., Odaga J., et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ 2013, 91:585-592.
33. GAVI. Countries eligible for support. 2015. Available at: . Accessed April 20, 2015. http://www.gavi.org/support/apply/countries-eligible-for-support.
34. Hanson C.M., Eckert L., Bloem P., et al. Gavi HPV programs: application to implementation. Vaccine 2015, 3:408-419.
35. Portnoy A., Ozawa S., Grewal S., et al. Costs of vaccine programs across 94 low- and middle-income countries. Vaccine 2015, 33(Suppl 1):A99-A108.
36. Andrus J.K., Sherris J., Fitzsimmons J.W., et al. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008, 26S:K87-K92.
37. Levin A., Wang S.A., Levin C., et al. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoS One 2014, 9:e101114.
38. Ladner J., Besson M.H., Rodrigues M., et al. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health 2014, 14:670.
39. Kaddar M., Schmitt S., Makinen M., et al. Global support for new vaccine implementation in middle-income countries. Vaccine 2013, 31(Suppl 2):B81-B96.
40. Elfstrom K.M., Dillner J., Arnheim-Dahlstrom L. Organization and quality of HPV vaccination programs in Europe. Vaccine 2015, 33:1673-1681.
41. Paul P., Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine 2014, 32:320-326.
42. LaMontagne D.S., Barge S., Le N.T., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011, 89:821-830. B.
43. Penny M., Bartolini R., Mosqueira N.R., et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011, 29:5022-5030.
44. Moodley I., Tathiah N., Mubaiwa V., et al. High uptake of Gardasil vaccine among 9-12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. S Afr Med J 2013, 103:318-321.
45. Fregnani J.H., Carvalho A.L., Eluf-Neto J., et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One 2013, 8:e62647.
46. Ladner J., Besson M.H., Hampshire R., et al. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012, 12:370.
47. Limper H.M., Burns J.L., Lloyd L.M., et al. Challenges to school-located vaccination: lessons learned. Pediatrics 2014, 134:803-808.
48. Caskey R.N., Macario E., Johnson D.C., et al. A school-located vaccination adolescent pilot initiative in Chicago: lessons learned. J Pediatr Infect Dis Soc 2013, 2:198-204.
49. Rickert V.I., Auslander B.A., Cox D.S., et al. School-based HPV immunization of young adolescents: effects of two brief health interventions. Hum Vaccin Immunother 2015, 11:315-321.
50. Nodulman J.A., Starling R., Kong A.S., et al. Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs. J Sch Health 2015, 85:289-298.
51. Orenstein W.A., Hinman A.R. The immunization system in the United States - the role of school immunization laws. Vaccine 1999, 17(Suppl):S19-S24.
52. Laugesen M.J., Mistry R., Carameli K.A., et al. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010. J Adolesc Health 2014, 55:659-664.
53. Pitts M.J., Adams Tufts K. Implications of the Virginia human papillomavirus vaccine mandate for parental vaccine acceptance. Qual Health Res 2013, 23:605-617.
54. Stokley S., Jeyarajah J., Yankey D., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014, 63:620-624.
55. Kester L.M., Zimet G.D., Fortenberry J.D., et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J 2013, 17:879-885.
56. Donahue K.L., Stupiansky N.W., Alexander A.B., et al. Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. Vaccine 2014, 32:3883-3885.
57. National Foundation for Infectious Diseases. Call to Action: HPV Vaccination as a Public Health Priority. 2014. Available at: . Accessed July 27, 2015. http://www.adolescentvaccination.org/hpv-cta.
58. Szilagyi P.G., Serwint J.R., Humiston S.G., et al. Effect of provider prompts on adolescent immunization rates: a randomized trial. Acad Pediatr 2015, 15:149-157.
59. Ruffin M.T., Plegue M.A., Rockwell P.G., et al. Impact of an electronic health record (EHR) reminder on human papillomavirus (HPV) vaccine initiation and timely completion. J Am Board Fam Med 2015, 28:324-333.
60. Kharbanda E.O., Stockwell M.S., Fox H.W., et al. Text message reminders to promote human papillomavirus vaccination. Vaccine 2011, 29:2537-2541.
61. Matheson E.C., Derouin A., Gagliano M., et al. Increasing HPV vaccination series completion rates via text message reminders. J Pediatr Health Care 2014, 28:e35-e39.
62. Rand C.M., Brill H., Albertin C., et al. Effectiveness of centralized text message reminders on human papillomavirus immunization coverage for publicly insured adolescents. J Adolesc Health 2015, 56(5 Suppl):S17-S20.
63. Bar-Shain D.S., Stager M.M., Runkle A.P., et al. Direct messaging to parents/guardians to improve adolescent immunizations. J Adolesc Health 2015, 56(5 Suppl):S21-S26.
64. Fu L.Y., Bonhomme L.A., Cooper S.C., et al. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine 2014, 32:1901-1920.
65. Mayne S., Karavite D., Grundmeier R.W., et al. The implementation and acceptability of an HPV vaccination decision support system directed at both clinicians and families. AMIA Annu Symp Proc 2012, 2012:616-624.
66. Fiks A.G., Grundmeier R.W., Mayne S., et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics 2013, 131:1114-1124.
67. Perkins R.B., Zisblatt L., Legler A., et al. Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls. Vaccine 2015, 33:1223-1229.
68. Gilkey M.B., Moss J.L., Roberts A.J., et al. Comparing in-person and webinar delivery of an immunization quality improvement program: a process evaluation of the adolescent AFIX trial. Implement Sci 2014, 9:21.
69. Dempsey A.F., Zimet G.D. Interventions to improve adolescent vaccination: what may work and what still needs to be tested. Am J Prev Med 2015, [Epub ahead of print].
70. Slattelid Schreiber S.M., Juul K.E., Dehlendorff C., et al. Socioeconomic predictors of human papillomavirus vaccination among girls in the Danish childhood immunization program. J Adolesc Health 2015, 56:402-407.
71. LaMontagne D.S., Nghi N.Q., Nga le T., et al. Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: evidence from a government-implemented demonstration program. BMC Public Health 2014, 14:556.
72. Sharma D.C. Rights violation found in HPV vaccine studies in India. Lancet Oncol 2013, 14:e443.
73. Sengupta A., Shenoi A., Sarojini N.B., et al. Human papillomavirus vaccine trials in India. Lancet 2011, 377:719.
74. Tsu V.D. Indian vaccine study clarified. Nature 2011, 475:296.
75. Lamontagne D.S., Sherris J.D. Addressing questions about the HPV vaccine project in India. Lancet Oncol 2013, 14:e492.
76. Sarojini N., Deepa V. Trials and tribulations: an expose of the HPV vaccine trials by the 72nd Parliamentary Standing Committee Report. Indian J Med Ethics 2013, 10:220-222.
77. Larson H.J., Brocard P., Garnett G. The India HPV-vaccine suspension. Lancet 2010, 376:572-573.
78. Towghi F. The biopolitics of reproductive technologies beyond the clinic: localizing HPV vaccines in India. Med Anthropol 2013, 32:325-342.
79. Biellik R., Levin C., Mugisha E., et al. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009, 27:6203-6209.
80. Kane M.A., Serrano B., de Sanjosé S., et al. Implementation of human papillomavirus immunization in the developing world. Vaccine 2012, 30:F192-F200.
81. Burchett H.E., Mounier-Jack S., Torres-Rueda S., et al. The impact of introducing new vaccines on the health system: case studies from six low- and middle-income countries. Vaccine 2014, 32:6505-6512.
82. Tsu V.D. Overcoming barriers and ensuring access to HPV vaccines in low-income countries. Am J Law Med 2009, 35:401-413.
83. Bingham A., Drake K., LaMontagne S. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009, 163:455-461.
84. Vermandere H., Naanyu V., Mabeya H., et al. Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS One 2014, 9:e109353.
85. Cunningham M.S., Davison C., Aronson K.J. HPV vaccine acceptability in Africa: a systematic review. Prev Med 2014, 69:274-279.
86. Bartolini R.M., Winkler J.L., Penny M.E., et al. Parental acceptance of HPV vaccine in Peru: a decision framework. PLoS One 2012, 7:e48017.
87. Wigle J., Coast E., Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low- and middle-income countries (LMICs): health system experiences and prospects. Vaccine 2013, 31:3811-3817.
88. Perlman S., Wamai R.G., Bain P.A., et al. Knowledge and awareness of HPV vaccine and acceptability to vaccine in sub-Saharan Africa: a systematic review. PLoS One 2014, 9:e90912.
89. Mugisha E., LaMontagne D.S., Katahoire A.R., et al. Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda. Afr Health Sci 2015, 15:33-41.
90. World Health Organization Comprehensive cervical cancer control: a guide to essential practice 2014, WHO, Geneva (Switzerland). 2nd edition.
91. Hindin M., Bloem P., Ferguson J. Effective nonvaccine interventions to be considered alongside human papilloma virus vaccine delivery. J Adolesc Health 2015, 56:10-18.